THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Desperate patients get early access to promising drug for multiple Life-Threatening conditions
Disease control AVAILABLEThis program offers early access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like myelofibrosis, severe COVID-19, and graft-versus-host disease who have no other treatment options. It is for people who cannot join a clinical trial and…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 03:53 UTC